Navigation Links
Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer
Date:11/30/2011

LAUSANNE, Switzerland, November 30, 2011 /PRNewswire/ --

Current Ceo Rudi Pauwels Becomes Executive Chairman Focusing On Scientific And Technology Strategy


New Ceo Appointment Strengthens Commercial Focus As Biocartis Prepares For Launch Of Its First Product In 2013

Biocartis, a company developing and commercializing compact molecular diagnostic (MDx) systems designed to drive personalized medicine and improve the diagnosis of disease, today announced the appointment of Dr. Nayan Gregory Parekh as its new Chief Executive Officer.

Parekh brings to Biocartis a wealth of pharmaceutical and biotechnology industry experience and has been an Executive Director of the Company's Board since April 2011. Rudi Pauwels, co-founder of Biocartis and current CEO, will become Executive Chairman and will dedicate his time to the Company's scientific and technology strategy.

Biocartis is moving into a new strategic phase as it focuses on building commercial capabilities and expanding industry partnerships. Dr. Parekh has held senior management positions at Novartis and Deutsche Bank and has a broad network of relationships and experience across a number of healthcare fields and geographies. Most recently, he was at New Rhein Healthcare LLC, a healthcare investment firm where he was one of the founding partners.  Before setting up New Rhein, Dr. Parekh spent six years as head of corporate development at Novartis AG, where he led the Novartis investments in Eye Care, Vaccines, Diagnostics, Generics, as well as certain emerging markets such as China, Saudi Arabia, Brazil and Russia.   He was also a member of the Novartis Group Finance Committee. Prior to joining Novartis in 2004, he spent ten years in investment banking, primarily focusing on the pharmaceutical and biotechnology sectors.  Greg holds a PhD from Northwestern University and received a B.A. in Economics and Political Science from the University of Rochester.

"Greg's broad industry and financial experience combined with his knowledge of the Company made him an ideal candidate to lead the next exciting stage of Biocartis' development," said Dr. Rudi Pauwels, Executive Chairman of Biocartis. "Under his leadership, I am confident Biocartis will successfully execute its strategy to make the healthcare benefits that molecular diagnostics provide an everyday reality for as many people as possible."  

Dr. Pauwels added, "I would like to thank the former Chairman, Dinko Valerio, for his leadership of the board and service to the company." Dr. Valerio will continue as a non-executive board member.

Commenting on his new role, Dr. Parekh said: "Biocartis has the potential to become the global leader in

point of care molecular diagnostics and drive the adoption of personalized medicine. With its experienced senior leadership team, the recent $100 million fundraising, its unique consortium business model and the committed support of its key strategic collaborators, Biocartis is well placed to introduce several molecular diagnostics systems that will deliver high-quality data in a timely manner and improve healthcare outcomes."

About Biocartis (www.biocartis.com)

Biocartis aims to transform the global diagnostics market by making personalized medicine an everyday reality. The challenge Biocartis addresses is to enable the broadest possible access to new technologies that will allow individual diagnoses to be made quickly based on a systematic analysis of the wealth of rapidly emerging biomarkers rather than solely on physiological symptoms as they are today.  Ending the 'one drug fits all' paradigm will empower physicians to make better diagnoses based on better information and help tackle efficacy failings and increasing healthcare costs.

Biocartis intends to become a fully integrated provider of novel, broadly applicable molecular diagnostics and immunodiagnostics solutions (instruments, analytical techniques, chemistries, sample preparation and other innovative tools) with high-value clinical assay menus. These solutions are designed to be compatible with deployment in a wide variety of health care settings, providing rapid, high-quality care close to the patient. Biocartis' vision is shared by its current collaborators which include bioMerieux and Janssen Pharmaceutica (J&J). Debiopharm Group™, as lead investor in the last investment round, also supports that vision.

Biocartis is currently developing two innovative systems that share a common user interface and design philosophy:

  • Apollo, a system designed for the MDx market, comprising an instrument, communication console and single use, disposable cartridges. This system can detect and quantify multiple DNA- or RNA-based biomarkers in a wide variety of patient sample types with truly minimal user intervention.
  • A second system that has been built around disposable, microfluidic cartridges with digitally encoded micro carriers for the rapid and sensitive detection of a broad range and number of biomarkers. The first product from this technology will focus on protein-based biomarkers and will allow Biocartis to enter the immunoassay market.

Biocartis was founded in 2007 by Dr. Rudi Pauwels (Co-founder of Tibotec, Virco and Galapagos Genomics), Prof. Philippe Renaud (Prof. at EPFL), and Nader Donzel (Co-founder of Scitec laboratory Automation). The company has raised more than €100 million in equity funding.
Biocartis SA is based at the EPFL's Innovation Square in Lausanne, Switzerland; it has a fully owned Belgian subsidiary in Mechelen and a Dutch subsidiary at the High Tech Campus in Eindhoven.

Contacts

Greg Parekh, CEO
Tel: +32-15-632-656
pr@biocartis.com

Hilde Windels, CFO
Tel: +32-15-632-663
pr@biocartis.com

Citigate Dewe Rogerson
David Dible/Chris Gardner
Tel : +44-(0)20-7638-9571
david.dible@citigatedr.co.uk/chris.gardner@citigatedr.co.uk



'/>"/>
SOURCE Biocartis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. bioMerieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics
3. Rhythm Names Lex Van der Ploeg Chief Scientific Officer
4. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
5. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
6. Rhythm Names Keith M. Gottesdiener Chief Executive Officer
7. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
8. OXIS International Names David Saloff as Chief Executive Officer
9. Numira Biosciences Names New Board Member
10. PrimeraDx Names Fayyaz Memon Vice President of Regulatory Affairs and Quality Assurance
11. Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... MedDay, a biotechnology company focused on ... of Catherine Moukheibir as Chairman of its Board of Directors. ... Jacques Garaud , who contributed to the rapid development of ... Catherine started her career in strategy consulting and investment ... London .  She held C-Suite level roles in some ...
(Date:4/26/2016)... ... April 27, 2016 , ... Cameron ... LLP as an associate in the firm’s Intellectual Property practice group. , Clients ... electromechanical patent applications. He has an electrical engineering and computer engineering background, and ...
(Date:4/26/2016)... ... 26, 2016 , ... The European Patent Office (EPO) today announced ... finalists for the European Inventor Award 2016 in the category "Non-European countries." The winners ... a ceremony in Lisbon on June 9th. , The human capacity to walk with ...
(Date:4/26/2016)... ... 2016 , ... Mr. Palmer created the RPO business for Ceridian and lead ... managed services contract in the U.S. intelligence community with The SI (a Lockheed Martin ... Younger, founder of Accolo. “We are growing and his experience guiding our expansion ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
Breaking Biology News(10 mins):